Nat Commun: The concentration of p-tau181 in plasma can be used as a potential biomarker for Alzheimer's disease in patients with Down syndrome

Down syndrome (DS) is one of the most common genetic disorders of intellectual development that affects more than 5.
8 million people worldwide
.

With the improvement of medical care, the life expectancy of patients has also increased significantly, and it is now over 60 years old

Down syndrome (DS) is one of the most common genetic disorders of intellectual development that affects more than 5.

However, age-related comorbidities also appeared at the same time
.

In particular, the lifetime risk of Alzheimer's disease (AD) in DS patients exceeds 90%

The lifetime risk of Alzheimer's disease (AD) in DS patients exceeds 90%

Previous studies have shown that plasma tau protein (p-tau181) phosphorylated at threonine 181 can predict the pathology of AD with high accuracy in the general population
.

Down syndrome and plasma p-tau181 concentration changes with age

Down syndrome and plasma p-tau181 concentration changes with age

In this study, the researchers determined that plasma p-tau181 can be used as a relevant biomarker for the onset of AD in individuals with DS
.

The study included a total of 366 DS adults (240 asymptomatic, 43 prodromal AD, 83 AD dementia, and 44 cognitively normal controls)

Researchers have determined that plasma p-tau181 can be used as a relevant biomarker for the onset of AD in individuals with DS

Correlation between plasma p-tau181 concentration and imaging biomarkers of Down syndrome

Correlation between plasma p-tau181 concentration and imaging biomarkers of Down syndrome

Using the single molecule array (Simoa) assay to measure the plasma p-tau181 concentration, the researchers tested the diagnostic performance of p-tau181 for AD and its relationship with other biomarkers
.

Plasma p-tau181 concentration can be used to distinguish asymptomatic individuals from individuals in the prodromal group and individuals in the dementia group.

Further studies have shown that plasma p-tau181 concentration is related to the atrophy and low metabolism of the temporal parietal area

Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome.

Leave a message here